Novartis AG is a multinational pharmaceutical company based in Switzerland.
The company was founded in 1996 through the merger of Ciba-Geigy and Sandoz.
With a market capitalization of over $250 billion, Novartis AG is one of the largest pharmaceutical companies in the world.
Novartis AG's diversified portfolio includes innovative medicines, eye care, and generic pharmaceuticals.
Broaden your view: Novartis Stock Symbol
Investor Insights
Novartis AG has a strong track record of innovation, with a pipeline of over 200 projects in development.
The company's focus on oncology and immunology has led to significant breakthroughs in treatments for diseases such as multiple sclerosis and leukemia.
Investors can expect continued growth from Novartis's existing products, particularly Alcon's eye care division, which has seen a significant increase in sales.
Bulls
As a bull on Novartis, I'm excited about the company's solid late-stage pipeline, which should propel long-term growth.
The company is expected to launch several new drugs in the next few years in critical therapeutic areas such as rare diseases and oncology.
These new launches will bring in much-needed revenue and help Novartis stay competitive in the market.
The rare diseases area is particularly promising, with Novartis' pipeline holding potential treatments for conditions that currently have limited options.
Dividend & Buyback
The Dividend & Buyback section of a company's financials is a crucial aspect for investors to consider. It reveals how the company is allocating its profits to shareholders and whether it's a good time to buy and hold.
The company's Dividend Yield is a respectable 3.41%, indicating a relatively stable income stream for investors. This is a key factor in determining the overall attractiveness of the stock.
A Dividend Payout Ratio of 0.64 suggests that the company is retaining a significant portion of its earnings, which can be a positive sign for future growth. This ratio is lower than the industry average, indicating that the company is being conservative with its dividend payments.
The 3-Year Dividend Growth Rate of 3.1% is a decent indicator of the company's commitment to returning value to shareholders. This growth rate is lower than some investors might expect, but it's still a positive sign.
Here are some key dividend metrics to consider:
The Shareholder Yield of 6.25% is a significant factor to consider, as it represents the total return to shareholders, including dividends and buybacks. This is a key metric for investors seeking to maximize their returns.
Financial Highlights
Novartis AG stock has some impressive financial highlights that are worth noting. The company's profitability metrics are strong, with a profit margin of 24.74% and a return on equity of 32.49%. This suggests that Novartis is able to generate a significant amount of profit from its sales.
One of the key drivers of Novartis' profitability is its revenue, which has reached $55.19 billion in the trailing 12 months. This is a significant increase from previous years, and it's likely due to the company's strong presence in the pharmaceutical industry.
Novartis' financial health is also impressive, with a total cash balance of $6.73 billion and a levered free cash flow of $14.68 billion. This suggests that the company has a strong cash position and is able to generate significant cash flow from its operations.
Here are some key financial metrics for Novartis AG stock:
Novartis' dividend yield is also worth noting, at 3.41%. This suggests that the company is committed to returning value to its shareholders through dividend payments. However, it's worth noting that the company's dividend payout ratio is 0.64, which suggests that a significant portion of its profits are being paid out to shareholders.
Key Statistics
Novartis Ag's market capitalization is a staggering 239.44 billion USD, making it a significant player in the market.
The company's shares outstanding total 2.19 billion, while the free float is 2.15 billion.
The average volume of shares traded is 1.9 million.
EPS (TTM) for Novartis Ag is 5.87 USD, indicating a strong earnings performance.
The price-to-earnings ratio (TTM) is 18.63, which is a reasonable valuation multiple.
Here's a summary of Novartis Ag's key statistics:
Novartis Ag's volatility is relatively high at 18.95%, indicating a stock that can be quite unpredictable.
Frequently Asked Questions
Is Novartis AG a buy or sell?
Novartis AG has a consensus rating of Hold, with 1 buy and 4 hold ratings from analysts. Currently, there's no upside potential, according to the analysts' average price target.
Is Novartis AG a public company?
Yes, Novartis AG is a publicly traded company, listed on the SIX Swiss Exchange. It is a publicly traded Swiss holding company with shares available for public purchase.
What is the 5 year return for Novartis?
The 5-year total return for Novartis is 22.6%, calculated from a 97.11 close price and a 79.20 adjusted prior close price. This significant return is a result of a prior price dividend adjustment factor of 0.83.
Is Novartis listed in the US?
Yes, Novartis is listed in the US, specifically on the New York Stock Exchange under the trading symbol "NVS". Its shares are priced in US dollars.
What is the difference between Novartis and Novartis AG?
Novartis AG is the parent company of the Novartis Group, a Swiss holding company. Novartis Pharmaceuticals Corporation (NPC) is the US subsidiary of Novartis AG, operating under a different name.
Featured Images: pexels.com
